Peptides / Recovery and repair

Synthetic analog · 11 amino acids · 1,257.3 Da

Cibinetide (ARA-290)

Not approvedBanned in sport

ARA-290, also called cibinetide, is a peptide designed from erythropoietin that acts on a tissue repair receptor without raising red blood cells. It is not approved, and small studies in people tested it on nerve damage, pain and the eye. PepBank shows 35 results on ARA-290 from 5 studies in people, and 331 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as pHBSP, ARA 290, ARA-290, ARA290, Cibinetide

11 amino acids, from first to lastXEQLERALNSS

Evidence level: Mostly animal studies331 of 366 results come from studies in animals and lab cells. 5 studies in people.

Results in people

10% of 366 results

Results in animals

243

66% of 366 results

Results in lab cells

24% of 366 results

From computer models

0% of 366 results

Overview

Cibinetide (ARA-290) at a glance

What it is	Synthetic analog, 11 amino acids
Approval	Not approved for any use
In sport	Banned in sport (WADA S2.1.5)
Studies	63 studies with results. 56 of them gave ARA-290, with 366 results. 35 in people243 in animals88 in lab cells
Best study in people	Randomized controlled trial with 64 people (2017)
Clinical trials	4 registered: 0 active or planned, 1 with posted results
Community use	Neuropathy and nerve pain (small fiber neuropathy); General neuroprotection and nerve recovery, sometimes stacked with BPC-157

The science

What is ARA-290?

Eleven-residue peptide designed from erythropoietin that activates the innate repair receptor without stimulating red-cell production.

Amino acids in one chain

The history of ARA-290

1999
The oldest paper on ARA-290 in PepBank is from 1999.
2012February
A registered trial of ARA-290 started (NCT02070783).

Cibinetide (ARA-290) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 11 amino acidsFrom the first amino acid to the last

X1−EQL−E5+RALNS10S

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Cibinetide (ARA-290) is a synthetic analog of 11 amino acids, with no ring, 1 changed amino acid.

Formula

C₅₁H₈₄N₁₆O₂₁

Molecular weight

1,257.3 g/mol

CAS number

1208243-50-8

Targets

Innate repair receptor (erythropoietin receptor and CD131 heterocomplex), EPOR subunit (gene EPOR): agonistEvidence: ChEMBL mechanismInnate repair receptor (erythropoietin receptor and CD131 heterocomplex), CD131 subunit (gene CSF2RB): agonistEvidence: ChEMBL mechanism

Development

Araim Pharmaceuticals, Inc. Highest phase: phase 2.

Identifiers

PubChem 91810664, ChEMBL CHEMBL3545305, UNII 9W5677JKDA, DrugBank DB13006, KEGG D11218, IUPHAR 9677

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH

InChIKey
WZTIQQBMSJTRBR-WYKNNRPVSA-N

SMILES
C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1

See charge, composition and 3D structure on the Scientific page

The evidence

What ARA-290 studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies331 of 366 results come from studies in animals and lab cells. 5 studies in people.

Brain and nerves

39 results · 7 in people · 24 animal · 8 lab

In people with sarcoidosis nerve fiber loss, 1 mg a day of cibinetide did not clearly change corneal nerve fiber area compared with placebo. Investigative ophthalmology & visual science, 2017

Top results

In people with sarcoidosis nerve fiber loss, 1 mg a day of cibinetide did not clearly change corneal nerve fiber area compared with placebo. (Investigative ophthalmology & visual science, 2017)
In diabetic rats, pHBSP reduced a stress response of supporting cells in the retina compared with scrambled peptide. (Diabetes, 2011)
In adults with type 2 diabetes and low corneal nerve fiber density, nerve fibers increased with ARA‑290 and did not change with placebo. (Molecular medicine, 2015)

Pain

20 results · 6 in people · 14 animal

In people with sarcoidosis nerve pain, pain improved in all groups; the abstract does not say whether cibinetide did better than placebo. Investigative ophthalmology & visual science, 2017

Top results

In people with sarcoidosis nerve pain, pain improved in all groups; the abstract does not say whether cibinetide did better than placebo. (Investigative ophthalmology & visual science, 2017)
In people with sarcoidosis and nerve symptoms, ARA‑290 improved a nerve symptom score at week 4 more than placebo did. (Molecular medicine, 2012)
In adults with type 2 diabetes, nerve pain symptoms improved more in the ARA‑290 group. (Molecular medicine, 2015)

Eyes

8 results · 6 in people · 2 animal

In people with diabetic macular edema, some, but not all, had better retinal thickness, tear production, diabetes control and urine protein after cibinetide. Journal of clinical medicine, 2020

Top results

In people with diabetic macular edema, some, but not all, had better retinal thickness, tear production, diabetes control and urine protein after cibinetide. (Journal of clinical medicine, 2020)
In people with diabetic macular edema, 12 weeks of cibinetide did not improve best corrected vision compared with the start. (Journal of clinical medicine, 2020)
In people with diabetic macular edema, 12 weeks of cibinetide did not improve retinal thickness compared with the start. (Journal of clinical medicine, 2020)

Mood, stress and behavior

6 results · 5 in people · 1 animal

In healthy adults, one week after ARA290, brain responses to happy faces were lower than with placebo. European neuropsychopharmacology, 2015

Top results

In healthy adults, one week after ARA290, brain responses to happy faces were lower than with placebo. (European neuropsychopharmacology, 2015)
In people with sarcoidosis and nerve symptoms, depression symptom scores did not change with ARA‑290. (Molecular medicine, 2012)
In healthy adults, ARA290 tended to lower recognition of happy faces compared with placebo, but the result was only a trend. (European neuropsychopharmacology, 2015)

Memory and thinking

10 results · 3 in people · 7 animal

In healthy adults, ARA290 did not improve memory for positive words compared with placebo. European neuropsychopharmacology, 2015

Top results

In healthy adults, ARA290 did not improve memory for positive words compared with placebo. (European neuropsychopharmacology, 2015)
In healthy adults, ARA290 was linked to faster sorting of positive and negative words than placebo. (European neuropsychopharmacology, 2015)
In healthy adults, ARA290 increased attention to positive pictures compared with placebo. (European neuropsychopharmacology, 2015)

Daily life and fitness

3 results · 2 in people · 1 animal

In people with sarcoidosis and nerve symptoms, the ARA‑290 group had a clear change from baseline in a physical function quality-of-life score. Molecular medicine, 2012

Top results

In people with sarcoidosis and nerve symptoms, the ARA‑290 group had a clear change from baseline in a physical function quality-of-life score. (Molecular medicine, 2012)
In people with sarcoidosis and nerve symptoms, tiredness scores improved about equally with ARA‑290 and with placebo. (Molecular medicine, 2012)
In rats with mild brain injury, pHBSP did not change movement ability compared with the inactive control peptide. (Journal of neurotrauma, 2013)

All 5 studies in people

In people

In people with sarcoidosis nerve fiber loss, 1 mg a day of cibinetide did not clearly change corneal nerve fiber area compared with placebo.

2017Investigative ophthalmology & visual science64 people

In people

In healthy adults, one week after ARA290, brain responses to happy faces were lower than with placebo.

2015European neuropsychopharmacology36 people

In people

In people with sarcoidosis and nerve symptoms, ARA‑290 improved a nerve symptom score at week 4 more than placebo did.

2012Molecular medicine22 people

In people

In people with diabetic macular edema, some, but not all, had better retinal thickness, tear production, diabetes control and urine protein after cibinetide.

2020Journal of clinical medicine9 people

In people

In adults with type 2 diabetes and low corneal nerve fiber density, nerve fibers increased with ARA‑290 and did not change with placebo.

2015Molecular medicine

All 63 ARA-290 studies by area Open the Scientific page

Key ARA-290 studies

Studies in people come first, then studies in animals and in the lab.

People
Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
Culver et al. 2017 · Investigative ophthalmology & visual science · 64 people · cited by 79
8 results
People
Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action
Cerit et al. 2015 · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 36 people · cited by 9
7 results
People
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
Heij et al. 2012 · Molecular medicine (Cambridge, Mass.) · 22 people · cited by 74
7 results
People
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema
Lois et al. 2020 · Journal of clinical medicine · 9 people · cited by 9
8 results
People
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Brines et al. 2015 · Molecular medicine (Cambridge, Mass.) · cited by 93
5 results

All 63 Cibinetide (ARA-290) studies

ARA-290 clinical trials

ClinicalTrials.gov lists 4 trials of ARA-290. 0 are active or planned, and 1 has posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

Phase 2completed64 people

Cognitive and Neural Effects of ARA290

Phase 1/2completed36 people

ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

Phase 2status unknown24 planned

All 2 Cibinetide (ARA-290) trials

Status and safety

Is ARA-290 approved?

FDA

United States

Investigational

Investigational.

EMA

European Union

Investigational

Investigational.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.1.5.

No. Not approved for any use. Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026). Banned in sport (WADA S2.1.5).

Laws and labels change, so check the regulator for the current status.

ARA-290 side effects and safety

PepBank has 10 safety results from studies of ARA-290. 4 of them come from studies in people.

Safety results from studies (10)

In people with sarcoidosis and nerve symptoms, tests and checks raised no safety concerns with ARA‑290 in this small study. (Molecular medicine, 2012)
In people with diabetic macular edema, no serious side effects were seen during 12 weeks of cibinetide. (Journal of clinical medicine, 2020)
In adults with type 2 diabetes, no potential safety issues were identified with ARA‑290 in this phase 2 study. (Molecular medicine, 2015)
In people with diabetic macular edema, no antibodies against cibinetide were found after 12 weeks of treatment. (Journal of clinical medicine, 2020)
In rats, pHBSP did not change hematocrit, the share of red blood cells in the blood. (Diabetes, 2011)
In mice fed a high-fat diet, pHBSP did not stimulate blood cell production. (Scientific reports, 2015)
In mice with lupus, ARA290 did not stimulate blood cell production during treatment. (Journal of cellular and molecular medicine, 2018)
In mice, ARA290 did not cause movement or behavior side effects, in both normal mice and mice lacking the β-common receptor. (PloS one, 2013)
In stressed mice, ARA290 changed blood hemoglobin and red cells only marginally. (Frontiers in pharmacology, 2022)
In diabetic rats, ARA290 did not change hematocrit, the share of red cells in blood. (Molecular medicine, 2016)

See every safety result on the Scientific page

Doses studied (31 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
1 mg/day	Human	human	Not reported	28 days	Randomized trial in people	Culver 2017
4 mg/day	Human	human	Not reported	28 days	Randomized trial in people	Culver 2017
8 mg/day	Human	human	Not reported	28 days	Randomized trial in people	Culver 2017
1, 4 and 8 mg/day	Human	human	Not reported	28 days	Randomized trial in people · n = 64	Culver 2017
2 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 36	Cerit 2015
2 mg three times weekly	Human	human	intravenous	4 weeks	Randomized trial in people · n = 22	Heij 2012
4 mg/day	Human	human	subcutaneous	12 weeks	Trial in people without random groups · n = 9	Lois 2020
4 mg	Human	human	subcutaneous	28 days daily, followed for a further month	Other study type	Brines 2015
30 μg/kg	Animal	rat	intraperitoneal	Every 12 h for 3 days	Study in live animals · n = 64	Robertson 2013
10 μg/kg per day	Animal	Rat	Not reported	1 month	Study in live animals · n = 24	McVicar 2011
30 μg/kg	Animal	rat	intraperitoneal	Daily from day 1 post surgery	Study in live animals · n = 11	Pulman 2013
120 μg/kg	Animal	rat	intraperitoneal	Daily from day 1 post surgery	Study in live animals · n = 9	Pulman 2013
1-30 μg/kg	Animal	Not reported	Not reported	Not reported	Study in live animals	McVicar 2011
30 μg/kg	Animal	Rat	intraperitoneal	Not reported	Study in live animals	Swartjes 2011
60 μg/kg	Animal	Rat	Not reported	single bolus	Study in live animals	Ahmet 2011
1 μg/kg	Animal	Rat	Not reported	single bolus	Study in live animals	Ahmet 2011
30 μg/kg every 12 h	Animal	Rat	Not reported	3 days	Study in live animals	Robertson 2012
3, 10, 30 and 60 μg/kg	Animal	rat	Not reported	Days 1, 3, 6, 8 and 10	Study in live animals	Swartjes 2014
10 and 30 μg/kg	Animal	rat	Not reported	Days 1, 3, 6, 8 and 10	Study in live animals	Swartjes 2014
10 μg/kg	Animal	rat	Not reported	Days 1, 3, 6, 8 and 10	Study in live animals	Swartjes 2014
30 μg/kg	Animal	rat	Not reported	Days 1, 3, 6, 8 and 10	Study in live animals	Swartjes 2014
30 and 120 μg/kg	Animal	rat	intraperitoneal	Daily from day 1 post surgery	Study in live animals	Pulman 2013
120 μg/kg	Animal	mouse	intraperitoneal	just before and at 0, 6, and 24 hours after transplantation	Study in live animals	Watanabe 2016
35, 70 μg/kg	Animal	rat	intraperitoneal	Once daily, Day 7 to Day 18 or Day 9 to Day 19	Study in live animals	Chen 2014
30 μg/kg	Animal	mouse	Not reported	Not reported	Study in live animals	Swartjes 2013
30 µg/kg	Animal	mouse	Not reported	Not reported	Study in live animals	Swartjes 2013
30 µg/kg	Animal	mouse	subcutaneous	up to 14 days	Study in live animals	Bitto 2018
120 µg/kg	Animal	mouse	Not reported	14 days	Study in live animals	Yao 2020
10 and 250 µg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Korokin 2020
50-400 nM	Lab	Not reported	Not reported	Not reported	Study on cells in a dish	Shokrzadeh 2020
50-400 nM	Lab	Not reported	Not reported	Not reported	Study on cells in a dish	Ghassemi-Barghi 2023

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

Community use of ARA-290 is very rare. The few reports describe injections under the skin once a day, mostly for nerve pain and neuropathy, and they copy the dose from small clinical trials (about 4 mg a day for 28 days).

Reported routines and cautions

What people use it for

Neuropathy and nerve pain (small fiber neuropathy)S1S2
General neuroprotection and nerve recovery, sometimes stacked with BPC-157S1S2

Reported regimens

Regimens that community sources report for ARA-290 (cibinetide). Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Neuropathy, standard protocol based on trial dosing	subcutaneous injection	2 to 4 mg per dose	once daily	28 to 84 days (S2 and S3: 28 days)	3 sources broadly agree on 4 mg a day under the skin; S1 allows 2 to 4 mg and up to 84 days. All three follow trial dosing, so they may not be independent. S1 and S3 carry seller links.	S1S2S3
Low-dose neuroprotective use	subcutaneous injection	1 to 8 mg per dose	once daily	4 to 8 weeks	sources differ: S1 says 1 to 2 mg, S2 says 1 to 8 mg a day. S1 carries seller links.	S1S2

Reported side effects

well tolerated with minimal side effects, in line with clinical trial safety dataS1

Reported benefits (claims, not shown in trials)

modest improvement in nerve symptoms in a small number of users with diagnosed neuropathy (self-reported)S1

Cautions

The number of community reports is extremely small (estimated fewer than 20 in total). Self-reported improvements are difficult to verify.S1
Product authenticity is a significant concern because the peptide is rare.S1
S3 says the evidence is small phase 2 trials with measured nerve-fiber changes. S3 says the drug never passed phase 2 and is grey-market only.S3

Status notes

ARA-290 (cibinetide) never passed phase 2 and is grey-market only, per one source that carries seller links (S3). No approval was found.S3

Community sources

S1ARA-290: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
S2Ara 290 (Cibinetide) (opens in a new tab)peptide-db.com
S3ARA-290 (Cibinetide)outliyr.comcarries seller links, not linked

Gaps

Almost no community use exists, and S1 says fewer than 20 reports. No forum threads were readable (Reddit is blocked). The amounts in all three sources come from trial dosing, not from user posts. ClinicalTrials.gov and PubMed pages could not be read by the checker. No harm-reduction or news source was found. The status note rests on one seller-linked page, so it is weak.

Questions and more

Ask a question about ARA-290

The answer links to every study it uses.

What does the evidence say about ARA-290?Is ARA-290 tested in people?Compare with Thymosin beta-4 (human)Compare with BPC-157

Sources

Database: PepBank data for ARA-290 (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about ARA-290

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Cibinetide (ARA-290)

Not approvedBanned in sport

Also known as pHBSP, ARA 290, ARA-290, ARA290, Cibinetide

What it is

Synthetic analog, 11 amino acids

Approval

Not approved for any use

In sport

Banned in sport (WADA S2.1.5)

Studies

63 studies with results. 56 of them gave ARA-290, with 366 results.
35 in people243 in animals88 in lab cells

Best study in people

Randomized controlled trial with 64 people (2017)

Clinical trials

4 registered: 0 active or planned, 1 with posted results

Community use

Neuropathy and nerve pain (small fiber neuropathy); General neuroprotection and nerve recovery, sometimes stacked with BPC-157

Dose as reported

Class

Species

Route

Duration

Design

Source

1 mg/day

Human

human

Not reported

28 days

Randomized trial in people

Culver 2017

4 mg/day

Human

human

Not reported

28 days

Randomized trial in people

Culver 2017

8 mg/day

Human

human

Not reported

28 days

Randomized trial in people

Culver 2017

1, 4 and 8 mg/day

Human

human

Not reported

28 days

Randomized trial in people · n = 64

Culver 2017

2 mg

Human

human

Not reported

Randomized trial in people · n = 36

Cerit 2015

2 mg three times weekly

Human

human

intravenous

4 weeks

Randomized trial in people · n = 22

Heij 2012

4 mg/day

Human

human

subcutaneous

12 weeks

Trial in people without random groups · n = 9

Lois 2020

4 mg

Human

human

subcutaneous

28 days daily, followed for a further month

Other study type

Brines 2015

30 μg/kg

Animal

rat

intraperitoneal

Every 12 h for 3 days

Study in live animals · n = 64

Robertson 2013

10 μg/kg per day

Animal

Rat

Not reported

1 month

Study in live animals · n = 24

McVicar 2011

30 μg/kg

Animal

rat

intraperitoneal

Daily from day 1 post surgery

Study in live animals · n = 11

Pulman 2013

120 μg/kg

Animal

rat

intraperitoneal

Daily from day 1 post surgery

Study in live animals · n = 9

Pulman 2013

1-30 μg/kg

Animal

Not reported

Study in live animals

McVicar 2011

30 μg/kg

Animal

Rat

intraperitoneal

Not reported

Study in live animals

Swartjes 2011

60 μg/kg

Animal

Rat

Not reported

single bolus

Study in live animals

Ahmet 2011

1 μg/kg

Animal

Rat

Not reported

single bolus

Study in live animals

Ahmet 2011

30 μg/kg every 12 h

Animal

Rat

Not reported

3 days

Study in live animals

Robertson 2012

3, 10, 30 and 60 μg/kg

Animal

rat

Not reported

Days 1, 3, 6, 8 and 10

Study in live animals

Swartjes 2014

10 and 30 μg/kg

Animal

rat

Not reported

Days 1, 3, 6, 8 and 10

Study in live animals

Swartjes 2014

10 μg/kg

Animal

rat

Not reported

Days 1, 3, 6, 8 and 10

Study in live animals

Swartjes 2014

30 μg/kg

Animal

rat

Not reported

Days 1, 3, 6, 8 and 10

Study in live animals

Swartjes 2014

30 and 120 μg/kg

Animal

rat

intraperitoneal

Daily from day 1 post surgery

Study in live animals

Pulman 2013

120 μg/kg

Animal

mouse

intraperitoneal

just before and at 0, 6, and 24 hours after transplantation

Study in live animals

Watanabe 2016

35, 70 μg/kg

Animal

rat

intraperitoneal

Once daily, Day 7 to Day 18 or Day 9 to Day 19

Study in live animals

Chen 2014

30 μg/kg

Animal

mouse

Not reported

Study in live animals

Swartjes 2013

30 µg/kg

Animal

mouse

Not reported

Study in live animals

Swartjes 2013

30 µg/kg

Animal

mouse

subcutaneous

up to 14 days

Study in live animals

Bitto 2018

120 µg/kg

Animal

mouse

Not reported

14 days

Study in live animals

Yao 2020

10 and 250 µg/kg

Animal

rat

Not reported

Study in live animals

Korokin 2020

50-400 nM

Lab

Not reported

Study on cells in a dish

Shokrzadeh 2020

50-400 nM

Lab

Not reported

Study on cells in a dish

Ghassemi-Barghi 2023

Context

Route

Amount

How often

How long

Agreement

Sources

Neuropathy, standard protocol based on trial dosing

subcutaneous injection

2 to 4 mg per dose

once daily

28 to 84 days (S2 and S3: 28 days)

3 sources broadly agree on 4 mg a day under the skin; S1 allows 2 to 4 mg and up to 84 days. All three follow trial dosing, so they may not be independent. S1 and S3 carry seller links.

S1S2S3

Low-dose neuroprotective use

subcutaneous injection

1 to 8 mg per dose

once daily

4 to 8 weeks

sources differ: S1 says 1 to 2 mg, S2 says 1 to 8 mg a day. S1 carries seller links.

S1S2

Cibinetide (ARA-290)

Cibinetide (ARA-290) at a glance

What is ARA-290?

The history of ARA-290

Cibinetide (ARA-290) structure and chemistry

What ARA-290 studies show

Brain and nerves

Pain

Eyes

Mood, stress and behavior

Memory and thinking

Daily life and fitness

All 5 studies in people

Key ARA-290 studies

ARA-290 clinical trials

Is ARA-290 approved?

ARA-290 side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about ARA-290

Related peptides

Sources

Cibinetide (ARA-290)

Cibinetide (ARA-290) at a glance

What is ARA-290?

The history of ARA-290

Cibinetide (ARA-290) structure and chemistry

What ARA-290 studies show

Brain and nerves

Pain

Eyes

Mood, stress and behavior

Memory and thinking

Daily life and fitness

All 5 studies in people

Key ARA-290 studies

ARA-290 clinical trials

Is ARA-290 approved?

ARA-290 side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about ARA-290

Related peptides

Sources